瑞莎珠单抗治疗活动性银屑病关节炎的疗效与安全性:KEEPsAKE 1 研究 52 周结果
KEEPsAKE 1 是一项全球 3 期研究,纳入对一种或多种传统合成改善病情抗风湿药应答不足或不耐受的活动性银屑病关节炎患者。第 24 周时,瑞莎珠单抗 150 mg 组 ACR20 应答率为 57.3%,安慰剂组为 33.5%(P < 0.001);第 52 周时,持续使用瑞莎珠单抗者 ACR20 应答率为 70.0%,第 1 期使用安慰剂、第 24 周起改用瑞莎珠单抗者为 63.0%。
要点
- 第 24 周 ACR20:瑞莎珠单抗组 57.3% vs 安慰剂组 33.5%(P < 0.001)
- 第 52 周 ACR20:持续瑞莎珠单抗组 70.0% vs 第 24 周换用组 63.0%
- 瑞莎珠单抗耐受性良好,第 24 周至第 52 周安全性特征一致
核心结论
- 在对传统合成改善病情抗风湿药应答不足或不耐受的活动性银屑病关节炎患者中,持续瑞莎珠单抗治疗至 52 周显示出稳健的长期疗效且耐受性良好。
研究设计与样本
- KEEPsAKE 1 是一项正在进行的全球 3 期研究,第 1 期为 24 周双盲、安慰剂对照期,第 2 期为开放标签延伸期。
- 第 1 期将符合条件的患者按 1:1 随机分配,分别在第 0、4、16 周皮下注射瑞莎珠单抗 150 mg 或安慰剂。
- 第 24 周起进入第 2 期,所有继续治疗的患者接受开放标签瑞莎珠单抗 150 mg,每 12 周一次,至第 208 周。
- 第 24 周时瑞莎珠单抗组 n = 483,安慰剂组 n = 481。
主要发现
- 第 24 周时,瑞莎珠单抗组 57.3%(n = 483)达到 ACR20,安慰剂组为 33.5%(n = 481),P < 0.001。
- 第 52 周时,第 1 期随机接受持续瑞莎珠单抗治疗的患者中 70.0% 达到 ACR20,第 1 期接受安慰剂、第 24 周起接受瑞莎珠单抗的患者中 63.0% 达到 ACR20。
- 其他疗效指标观察到相似的结果趋势。
- 瑞莎珠单抗治疗至 52 周耐受性良好,第 24 周至第 52 周安全性特征一致。
关键数值与推荐
- 第 24 周 ACR20 应答率:瑞莎珠单抗 150 mg 组 57.3% vs 安慰剂组 33.5%(P < 0.001)。
- 第 52 周 ACR20 应答率:持续瑞莎珠单抗组 70.0% vs 第 1 期安慰剂、第 24 周起瑞莎珠单抗组 63.0%。
- 给药方案:第 1 期瑞莎珠单抗 150 mg 皮下注射于第 0、4、16 周;第 2 期开放标签瑞莎珠单抗 150 mg 每 12 周一次至第 208 周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated. METHODS: KEEPsAKE 1 is an ongoing, global, phase 3 study with a 24-week, double-blind, placebo-controlled period (period 1) and an open-label extension period (period 2). In period 1, eligible patients were randomized 1:1 to receive subcutaneous risankizumab 150 mg or placebo at weeks 0, 4 and 16. At week 24 (period 2), all continuing patients received open-label risankizumab 150 mg every 12 weeks through week 208. RESULTS: At week 24, 57.3% of risankizumab-treated patients (n = 483) achieved ≥20% improvement in ACR criteria (ACR20) vs 33.5% of placebo-treated patients (n = 481; P < 0.001). At week 52, 70.0% of patients who were randomized to receive continuous risankizumab therapy and 63.0% of patients who were randomized to receive placebo in period 1 and then receive risankizumab at week 24 achieved ACR20. Similar result trends were observed for other efficacy measures. Risankizumab was well tolerated through 52 weeks of treatment with a consistent safety profile from week 24 through week 52. CONCLUSION: In patients with active PsA who were csDMARD-IR, continuous risankizumab treatment demonstrated robust long-term efficacy and was well tolerated through 52 weeks of treatment. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, KEEPsAKE1, NCT03675308.
引用
- Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2023. PMID: 36282530. doi:10.1093/rheumatology/keac607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。